Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.

Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H.

Br J Haematol. 2018 Jun 8. doi: 10.1111/bjh.15204. [Epub ahead of print] No abstract available.

PMID:
29882583
2.

Management of patients with acute promyelocytic leukemia.

Kayser S, Schlenk RF, Platzbecker U.

Leukemia. 2018 Jun;32(6):1277-1294. doi: 10.1038/s41375-018-0139-4. Epub 2018 Apr 24. Review.

PMID:
29743722
3.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.

Leukemia. 2018 Apr 17. doi: 10.1038/s41375-018-0129-6. [Epub ahead of print]

PMID:
29720733
4.

Acute myelogenous leukemia in adolescents and young adults.

Creutzig U, Kutny MA, Barr R, Schlenk RF, Ribeiro RC.

Pediatr Blood Cancer. 2018 Apr 18:e27089. doi: 10.1002/pbc.27089. [Epub ahead of print] Review.

PMID:
29667722
5.

A new option for remission induction in acute myeloid leukaemia.

Müller-Tidow C, Schlenk RF.

Lancet Oncol. 2018 Feb;19(2):156-157. doi: 10.1016/S1470-2045(18)30012-3. Epub 2018 Jan 12. No abstract available.

PMID:
29339096
6.

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.

Zajac M, Dolnik A, Stasiak G, Zaleska J, Kielbus M, Czapinski J, Schunn M, Correa SC, Glodkowska-Mrowka E, Sundaram RC, Jankowska-Lecka O, Schlenk RF, Döhner H, Döhner K, Stepulak A, Bullinger L, Giannopoulos K.

Oncotarget. 2017 Aug 3;8(56):95163-95175. doi: 10.18632/oncotarget.19871. eCollection 2017 Nov 10.

7.

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.

Wais V, Kündgen L, Bohl SR, von Harsdorf S, Schlenk RF, Döhner K, Teleanu V, Bullinger L, Nguyen TM, Drognitz K, Moulin JC, Binnenhei M, Bentz M, Döhner H, Bunjes D, Kuchenbauer F, Ringhoffer M.

Bone Marrow Transplant. 2018 Jan;53(1):94-96. doi: 10.1038/bmt.2017.211. Epub 2017 Nov 13. No abstract available.

PMID:
29131153
8.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).

Ann Hematol. 2017 Dec;96(12):1993-2003. doi: 10.1007/s00277-017-3150-3. Epub 2017 Oct 31.

9.

Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.

Schlenk RF, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, Pabst T, Vusirikala M, Bouscary D, Spencer A, Candoni A, Gil JS, Berkowitz N, Weber HJ, Ottmann O.

Haematologica. 2018 Jan;103(1):e25-e28. doi: 10.3324/haematol.2017.172411. Epub 2017 Oct 19. No abstract available.

10.

Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype.

Hörster L, Schlenk RF, Stadler M, Gabriel M, Thol F, Schildmann J, Vollmann J, Rochau U, Sroczynski G, Wasem J, Ganser A, Port M, Neumann A.

Leuk Res. 2017 Nov;62:84-90. doi: 10.1016/j.leukres.2017.09.009. Epub 2017 Sep 19.

PMID:
28988037
11.

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.

Hirsch S, Blätte TJ, Grasedieck S, Cocciardi S, Rouhi A, Jongen-Lavrencic M, Paschka P, Krönke J, Gaidzik VI, Döhner H, Schlenk RF, Kuchenbauer F, Döhner K, Dolnik A, Bullinger L.

Haematologica. 2017 Dec;102(12):2039-2047. doi: 10.3324/haematol.2017.172866. Epub 2017 Sep 29.

12.

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Kayser S, Levis MJ, Schlenk RF.

Expert Rev Clin Pharmacol. 2017 Nov;10(11):1177-1189. doi: 10.1080/17512433.2017.1387051. Epub 2017 Oct 10. Review.

PMID:
28960095
13.

Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.

Kayser S, Feszler M, Krzykalla J, Schick M, Kramer M, Benner A, Thol F, Platzbecker U, Müller-Tidow C, Ho AD, Ehninger G, Heuser M, Schlenk RF, Thiede C, Röllig C, Krämer A.

Eur J Haematol. 2017 Dec;99(6):544-552. doi: 10.1111/ejh.12972. Epub 2017 Oct 13.

PMID:
28940816
14.

Relapsed/refractory acute myeloid leukemia: any progress?

Schlenk RF, Müller-Tidow C, Benner A, Kieser M.

Curr Opin Oncol. 2017 Nov;29(6):467-473. doi: 10.1097/CCO.0000000000000404. Review.

PMID:
28857842
15.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.

N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.

16.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

PMID:
28643785
17.

Precision oncology based on omics data: The NCT Heidelberg experience.

Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S.

Int J Cancer. 2017 Sep 1;141(5):877-886. doi: 10.1002/ijc.30828. Epub 2017 Jun 21.

PMID:
28597939
18.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.

Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45.

19.

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.

Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D.

Ann Hematol. 2017 Jun;96(6):887-894. doi: 10.1007/s00277-017-2983-0. Epub 2017 Apr 3.

PMID:
28374162
20.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.

Kayser S, Krzykalla J, Elliott MA, Norsworthy K, Gonzales P, Hills RK, Baer MR, Ráčil Z, Mayer J, Novak J, Žák P, Szotkowski T, Grimwade D, Russell NH, Walter RB, Estey EH, Westermann J, Görner M, Benner A, Krämer A, Smith BD, Burnett AK, Thiede C, Röllig C, Ho AD, Ehninger G, Schlenk RF, Tallman MS, Levis MJ, Platzbecker U.

Leukemia. 2017 Nov;31(11):2347-2354. doi: 10.1038/leu.2017.92. Epub 2017 Mar 21.

21.

A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises.

Schönsteiner SS, Bauder Mißbach H, Benner A, Mack S, Hamel T, Orth M, Landwehrmeyer B, Süßmuth SD, Geitner C, Mayer-Steinacker R, Riester A, Prokein A, Erhardt E, Kunecki J, Eisenschink AM, Rawer R, Döhner H, Kirchner E, Schlenk RF.

Exp Hematol Oncol. 2017 Feb 7;6:5. doi: 10.1186/s40164-017-0065-6. eCollection 2017.

22.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.

Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19.

PMID:
28138160
23.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; the German-Austrian AMLSG.

Leukemia. 2017 May;31(5):1217-1220. doi: 10.1038/leu.2017.22. Epub 2017 Jan 18. No abstract available.

24.

Precision oncology for acute myeloid leukemia using a knowledge bank approach.

Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H, Campbell PJ.

Nat Genet. 2017 Mar;49(3):332-340. doi: 10.1038/ng.3756. Epub 2017 Jan 16.

25.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.

Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.

Leukemia. 2017 Apr;31(4):1012-1015. doi: 10.1038/leu.2017.18. Epub 2017 Jan 16. No abstract available.

PMID:
28090090
26.

Is there justification for 4 cycles of consolidation therapy in AML?

Schlenk RF.

Best Pract Res Clin Haematol. 2016 Dec;29(4):341-344. doi: 10.1016/j.beha.2016.10.008. Epub 2016 Oct 20. Review.

PMID:
27890257
27.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichmann M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk RF, Döhner K, Döhner H, Ganser A, Heuser M.

Leukemia. 2017 Jun;31(6):1286-1295. doi: 10.1038/leu.2016.345. Epub 2016 Nov 24.

PMID:
27881874
28.

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

Ann Hematol. 2016 Dec;95(12):1931-1942. Epub 2016 Oct 3.

29.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2282. doi: 10.1038/leu.2016.207. No abstract available.

PMID:
27804971
30.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.

Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. No abstract available.

PMID:
27375010
31.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2160-2168. doi: 10.1038/leu.2016.126. Epub 2016 May 3. Erratum in: Leukemia. 2016 Nov;30(11):2282.

PMID:
27137476
32.

MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses.

Shivarov V, Dolnik A, Lang KM, Krönke J, Kuchenbauer F, Paschka P, Gaidzik VI, Döhner H, Schlenk RF, Döhner K, Bullinger L.

Haematologica. 2016 Nov;101(11):e454-e456. Epub 2016 Jul 28. No abstract available.

33.

The genomic landscape of core-binding factor acute myeloid leukemias.

Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner K, Döhner H, Bullinger L, Zhang J, Klco JM, Downing JR.

Nat Genet. 2016 Dec;48(12):1551-1556. doi: 10.1038/ng.3709. Epub 2016 Oct 31.

34.

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

Schlenk RF, Stegelmann F, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K.

Leukemia. 2017 Apr;31(4):889-895. doi: 10.1038/leu.2016.299. Epub 2016 Oct 24.

PMID:
27774990
35.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol. 2017 Feb 20;35(6):605-612. doi: 10.1200/JCO.2016.67.1982. Epub 2016 Oct 31.

36.

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers.

Lueck SC, Russ AC, Botzenhardt U, Schlenk RF, Zobel K, Deshayes K, Vucic D, Döhner H, Döhner K, Fulda S, Bullinger L.

Oncotarget. 2016 Aug 2;7(31):49539-49551. doi: 10.18632/oncotarget.10390.

37.

Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.

Rücker FG, Lang KM, Fütterer M, Komarica V, Schmid M, Döhner H, Schlenk RF, Döhner K, Knudsen S, Bullinger L.

Epigenetics. 2016 Jul 2;11(7):517-25. doi: 10.1080/15592294.2016.1187350. Epub 2016 Jun 16.

38.

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O'Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ.

N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192.

39.

Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling.

Hieke S, Benner A, Schlenk RF, Schumacher M, Bullinger L, Binder H.

PLoS One. 2016 May 9;11(5):e0155226. doi: 10.1371/journal.pone.0155226. eCollection 2016.

40.

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).

Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S, Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann WK, Germing U, Nolte F.

Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2. No abstract available.

PMID:
27133825
41.

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.

Hütter-Krönke ML, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne CH, Horst HA, Schmidt-Wolf IG, Rummel M, Götze K, Koller E, Petzer AL, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff AC, Ganser A, Döhner H, Schlenk RF.

Haematologica. 2016 Jul;101(7):839-45. doi: 10.3324/haematol.2015.141622. Epub 2016 Apr 1.

42.

Targeted Therapy Alone for Acute Promyelocytic Leukemia.

Lo-Coco F, Di Donato L; GIMEMA, Schlenk RF; German–Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia.

N Engl J Med. 2016 Mar 24;374(12):1197-8. doi: 10.1056/NEJMc1513710. No abstract available.

43.

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.

Bohl S, von Harsdorf S, Mulaw M, Hofmann S, Babiak A, Maier CP, Schnell J, Hütter-Krönke LM, Scholl K, Wais V, Schlenk RF, Bullinger L, Ringhoffer M, Döhner H, Bunjes D, Bommer M, Kuchenbauer F.

Bone Marrow Transplant. 2016 Jul;51(7):994-6. doi: 10.1038/bmt.2016.4. Epub 2016 Mar 7. No abstract available.

44.

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U.

Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15. No abstract available.

PMID:
26668126
45.

Minimal residual disease in acute myeloid leukemia--current status and future perspectives.

Kayser S, Walter RB, Stock W, Schlenk RF.

Curr Hematol Malig Rep. 2015 Jun;10(2):132-44. doi: 10.1007/s11899-015-0260-7. Review.

PMID:
25994952
46.

How I treat refractory and early relapsed acute myeloid leukemia.

Thol F, Schlenk RF, Heuser M, Ganser A.

Blood. 2015 Jul 16;126(3):319-27. doi: 10.1182/blood-2014-10-551911. Epub 2015 Apr 7. Review.

47.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.

Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk RF.

Br J Haematol. 2015 Jun;169(5):694-700. doi: 10.1111/bjh.13353. Epub 2015 Mar 29.

PMID:
25818407
48.

Minimal residual disease-directed therapy in acute myeloid leukemia.

Kayser S, Schlenk RF, Grimwade D, Yosuico VE, Walter RB.

Blood. 2015 Apr 9;125(15):2331-5. doi: 10.1182/blood-2014-11-578815. Epub 2015 Jan 28. Review. No abstract available.

49.

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.

Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.

Haematologica. 2015 Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16.

50.

Post-remission therapy for acute myeloid leukemia.

Schlenk RF.

Haematologica. 2014 Nov;99(11):1663-70. doi: 10.3324/haematol.2014.114611. Review.

Supplemental Content

Loading ...
Support Center